Abstract
A lack of druggable targets in the insulin-Akt pathway has made increasing insulin signaling an uphill struggle. Now, a Johns Hopkins team has found that Akt is inhibited by an inositol-derived signaling molecule called IP7, which could potentially provide a new angle for targeting diabetes and obesity.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
